Blueprint Medicines BPMC Stock
Blueprint Medicines Price Chart
Blueprint Medicines BPMC Financial and Trading Overview
Blueprint Medicines stock price | 86.82 USD |
Previous Close | 58.76 USD |
Open | 58.19 USD |
Bid | 0 USD x 1100 |
Ask | 0 USD x 1400 |
Day's Range | 57.68 - 61 USD |
52 Week Range | 37.82 - 79.4 USD |
Volume | 582.59K USD |
Avg. Volume | 568.35K USD |
Market Cap | 3.68B USD |
Beta (5Y Monthly) | 0.704929 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -8.37 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 73.18 USD |
BPMC Valuation Measures
Enterprise Value | 3.1B USD |
Trailing P/E | N/A |
Forward P/E | -7.8669252 |
PEG Ratio (5 yr expected) | 0.07 |
Price/Sales (ttm) | 17.99608 |
Price/Book (mrq) | 8.879976 |
Enterprise Value/Revenue | 15.152 |
Enterprise Value/EBITDA | -5.718 |
Trading Information
Blueprint Medicines Stock Price History
Beta (5Y Monthly) | 0.704929 |
52-Week Change | 25.21% |
S&P500 52-Week Change | 20.43% |
52 Week High | 79.4 USD |
52 Week Low | 37.82 USD |
50-Day Moving Average | 52.93 USD |
200-Day Moving Average | 50.85 USD |
BPMC Share Statistics
Avg. Volume (3 month) | 568.35K USD |
Avg. Daily Volume (10-Days) | 719.06K USD |
Shares Outstanding | 60.47M |
Float | 59.92M |
Short Ratio | 5.88 |
% Held by Insiders | 0.74% |
% Held by Institutions | 107.34% |
Shares Short | 3.69M |
Short % of Float | 8.25% |
Short % of Shares Outstanding | 6.11% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -284.018% |
Operating Margin (ttm) | -271.72% |
Gross Margin | 88.81% |
EBITDA Margin | -264.98% |
Management Effectiveness
Return on Assets (ttm) | -29.39% |
Return on Equity (ttm) | -89.67% |
Income Statement
Revenue (ttm) | 204.59M USD |
Revenue Per Share (ttm) | 3.42 USD |
Quarterly Revenue Growth (yoy) | 0.89% |
Gross Profit (ttm) | 177.28M USD |
EBITDA | -542129984 USD |
Net Income Avi to Common (ttm) | -581078016 USD |
Diluted EPS (ttm) | -10.26 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 822.16M USD |
Total Cash Per Share (mrq) | 13.6 USD |
Total Debt (mrq) | 240.34M USD |
Total Debt/Equity (mrq) | 58.01 USD |
Current Ratio (mrq) | 5.214 |
Book Value Per Share (mrq) | 6.857 |
Cash Flow Statement
Operating Cash Flow (ttm) | -492512000 USD |
Levered Free Cash Flow (ttm) | -221860880 USD |
Profile of Blueprint Medicines
Country | United States |
State | MA |
City | Cambridge |
Address | 45 Sidney Street |
ZIP | 02139 |
Phone | 617 374 7580 |
Website | https://www.blueprintmedicines.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 651 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Q&A For Blueprint Medicines Stock
What is a current BPMC stock price?
Blueprint Medicines BPMC stock price today per share is 86.82 USD.
How to purchase Blueprint Medicines stock?
You can buy BPMC shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Blueprint Medicines?
The stock symbol or ticker of Blueprint Medicines is BPMC.
Which industry does the Blueprint Medicines company belong to?
The Blueprint Medicines industry is Biotechnology.
How many shares does Blueprint Medicines have in circulation?
The max supply of Blueprint Medicines shares is 61.23M.
What is Blueprint Medicines Price to Earnings Ratio (PE Ratio)?
Blueprint Medicines PE Ratio is now.
What was Blueprint Medicines earnings per share over the trailing 12 months (TTM)?
Blueprint Medicines EPS is -8.37 USD over the trailing 12 months.
Which sector does the Blueprint Medicines company belong to?
The Blueprint Medicines sector is Healthcare.
Blueprint Medicines BPMC included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16103.45 USD — |
+0.82
|
4.52B USD — | 16094.17 USD — | 16247.59 USD — | — - | 4.52B USD — |
Nasdaq US 700 Small Cap Value N NQUS700SCVN | 2257.06 USD — |
-0.73
|
— — | 2256.98 USD — | 2273.86 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2078.81 USD — |
-0.4
|
— — | 2075.76 USD — | 2093.28 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7837.41 USD — |
+0.85
|
— — | 7832.7 USD — | 7908.95 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19565.06 USD — |
+0.82
|
— — | 19553.78 USD — | 19740.18 USD — | — - | — — |
Nasdaq US 700 Small Cap Value I NQUS700SCV | 2033.66 USD — |
-0.73
|
— — | 2033.59 USD — | 2048.8 USD — | — - | — — |
Nasdaq US Smart Pharmaceuticals NQSSPH | 1454.2 USD — |
-0.47
|
— — | 1453.71 USD — | 1464.83 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2568.29 USD — |
+0.16
|
— — | 2566.7 USD — | 2581.47 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4337.34 USD — |
-0.65
|
— — | 4335.84 USD — | 4376.86 USD — | — - | — — |
NASDAQ HealthCare IXHC | 986.88 USD — |
-0.25
|
— — | 986.44 USD — | 994.67 USD — | — - | — — |
NASDAQ Biotechnology Total Retu XNBI | 4654.3 USD — |
-0.65
|
— — | 4652.69 USD — | 4696.7 USD — | — - | — — |
- {{ link.label }} {{link}}